Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures
17 Outubro 2023 - 11:22AM
Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial
Biology Company®, today announced that researchers from Akoya
Biosciences and The University of Queensland’s Frazer Institute
have comprehensively mapped the spatial proteome of head and neck
squamous cell carcinoma (HNSCC) using ultrahigh-plex spatial
phenotyping. Spatial phenotyping consists of whole-slide imaging of
tissue sections at single-cell resolution to visualize and
quantitate biomarker expression and reveal how cells interact and
organize across the entire tissue landscape.
The study, published in GEN Biotechnology in an article titled
“Mapping the Spatial Proteome of Head and Neck Tumors: Key Immune
Mediators and Metabolic Determinants in the Tumor Microenvironment”
identified a high degree of intra- and inter-tumoral heterogeneity
intrinsic to head and neck cancers and advances the understanding
of the mechanistic basis of variable clinical responses.
The study analyzed head and neck cancer tissues from a patient
with varying responses to immune checkpoint inhibitor (ICI)
therapy. The analysis was conducted using a panel of 100+
biomarkers to measure key cancer hallmarks of tumor and immune
biology with Akoya’s PhenoCycler®-Fusion system.
The PhenoCycler-Fusion is the fastest spatial biology solution
available which enables rapid imaging of whole slides at
single-cell resolution.
“This study represents a significant advancement in multiplexed
imaging and, to our knowledge, is the first single-cell spatial
proteomic dataset integrating information from immune, metabolic
and stress pathways to provide a holistic view into the biology of
heterogenous HNSCC tumors” noted Niyati Jhaveri, PhD, Head of
Applications at Akoya Biosciences. “It provides an analytical
framework for future spatial studies leveraging the resolution,
plex and speed of Akoya’s solution to decipher the complex nuances
of human tissues in homeostasis and disease.”
A pivotal discovery in the study highlighted the divergent
enrichment of functionally specialized immune cell subsets, as well
as distinct metabolic and stress signatures organized within
specific spatial domains in the tumor. This overarching observation
in the paper underscored the existence of heterogeneous niches and
competitive microenvironments, potentially serving as defining
factors for clinical response and resistance.
“Immune checkpoint inhibitors have shown promising results in
recurrent and metastatic cases of HNSCC,” said Dr. Arutha
Kulasinghe, of The University of Queensland’s Frazer Institute,
leader of the Clinical-oMx Lab, and one of the paper’s authors.
“Durable treatment results, however, are observed in only 30% of
patients, indicating that new biomarkers for stratification of
responders and non-responders are needed. The dichotomy of immune
activation-induced death and tumor progression we observed in an
individual patient’s tissue sample correlated with the partial
response seen with ICI therapy. We believe that the approach
outlined in this study will pave the way towards a new
understanding of tumor microenvironment features associated with
response and sensitivity to immune checkpoint inhibitor therapies
in head and neck cancer and other solid malignancies.”
Forward-Looking Statements
This press release contains forward-looking statements that are
based on management’s beliefs and assumptions and on information
currently available to management. All statements contained in this
release other than statements of historical fact are
forward-looking statements, including statements regarding our
expectations about the potential of our products and services and
other matters regarding our business strategies and plans and
objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is
to bring context to the world of biology and human health through
the power of spatial phenotyping. The company offers comprehensive
single-cell imaging solutions that allow researchers to phenotype
cells with spatial context and visualize how they organize and
interact to influence disease progression and response to therapy.
Akoya offers a full continuum of spatial phenotyping solutions to
serve the diverse needs of researchers across discovery,
translational and clinical research: PhenoCode™ Panels and
PhenoCycler®, PhenoImager® Fusion, and PhenoImager HT
Instruments.
Investor Contact:Priyam ShahSr. Director,
Investor RelationsAkoya Biosciencesinvestors@akoyabio.com
Media Contact:Christine
Quern617-650-8497media@akoyabio.com
Akoya BioSciences (NASDAQ:AKYA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Akoya BioSciences (NASDAQ:AKYA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024